Precision medicine enabled histology agnostic development of immunotherapeutics
Update: 2017-07-31
Description
Prof Baynes speaks with ecancer at WIN 2017 about design and development of immune therapies sensitive to mutational deficiencies in the DNA repair pathway
He notes the recent approval of pembrolizumab (Keytruda) PD1 therapy for relapsed cancer patients with a high mutational burden determined with a micro-satellite instability assay.
Prof Baynes outlines the ongoing trials combining checkpoint immunotherapy with targeted agents such as tyrosine kinases, radiotherapy and chemotherapy, including results alongside other immuno-modulatory agents such as oncolytic viruses.
He notes the recent approval of pembrolizumab (Keytruda) PD1 therapy for relapsed cancer patients with a high mutational burden determined with a micro-satellite instability assay.
Prof Baynes outlines the ongoing trials combining checkpoint immunotherapy with targeted agents such as tyrosine kinases, radiotherapy and chemotherapy, including results alongside other immuno-modulatory agents such as oncolytic viruses.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
